20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years | Zendy

Hongchao Pan | Zendy; Richard Gray | Zendy; Jeremy Braybrooke | Zendy; Christina Davies | Zendy; Carolyn Taylor | Zendy; Paul McGale | Zendy; Richard Peto | Zendy; Kathleen I. Pritchard | Zendy; Jonas Bergh | Zendy; Mitch Dowsett | Zendy; Daniel F. Hayes | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

Author(s) -

Hongchao Pan,

Richard Gray,

Jeremy Braybrooke,

Christina Davies,

Carolyn Taylor,

Paul McGale,

Richard Peto,

Kathleen I. Pritchard,

Jonas Bergh,

Mitch Dowsett,

Daniel F. Hayes

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1701830

Subject(s) - medicine , breast cancer , oncology , proportional hazards model , cancer , endocrine system , stage (stratigraphy) , disease , gynecology , hormone , paleontology , biology

The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research